Imunon, Inc. Common Stock (IMNN) is a publicly traded Healthcare sector company. As of May 21, 2026, IMNN trades at $2.21 with a market cap of $9.50M and a P/E ratio of -0.32. IMNN moved -1.35% today. Year to date, IMNN is -46.08%; over the trailing twelve months it is -63.10%. Its 52-week range spans $2.08 to $41.22. Analyst consensus is strong buy with an average price target of $15.67. Rallies surfaces IMNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Imunon Outlines Q1 2026 Clinical Milestones and Funding Strategy: Imunon’s Q1 2026 earnings call transcript details clinical program updates, with executives reporting advancement of lead immuno-oncology candidates in early-stage trials and plans to initiate follow-on financing. Management reiterated timelines for key pipeline milestones through 2026 and outlined strategies to extend cash runway.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $9.50M |
| P/E Ratio | -0.32 |
| EPS | $-6.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.22 |
| 52-Week Low | $2.08 |
| Volume | 273 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-14.50M |
| Gross Margin | 0.00% |
3 analysts cover IMNN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.67.